Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bosakitug - Biosion

Drug Profile

Bosakitug - Biosion

Alternative Names: Anti-TSLP mAb; BSI-045B; TQC-2731

Latest Information Update: 18 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosion
  • Developer Biosion; Chia Tai Tianqing Pharmaceutical Group
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis; Rhinosinusitis
  • Phase I Chronic obstructive pulmonary disease; Hypersensitivity

Most Recent Events

  • 18 Oct 2023 Phase-II clinical trials in Rhinosinusitis in China (SC) (NCT06036927)
  • 10 Jul 2023 Biosion plans the proof-of-concept phase IIa ADAMANT trial for Atopic dermatitis (Monotherapy, Adjunctive treatment) in USA (SC, Injection), in July 2023 , (NCT05932654)
  • 06 Apr 2023 Phase-II clinical trials in Atopic dermatitis (Combination therapy) in USA (SC) (NCT05932654)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top